←TEMTempus AIOur view: UnattractiveFull analysisעברית
Updated 16 Nov 2026
The company · 1 · Who is this company?

Tempus is a cancer-testing lab with a data library

Tumour tests

read a tumour's DNA and RNA

Hereditary tests

inherited cancer risk

Data library

drugmakers pay to use it

Tempus reads a tumour's genes and reports the drugs and trials it may respond to. Insurers pay per test, and drugmakers pay to use the resulting data.

The company · 2 · What exactly does it sell?

Testing is three-quarters, data a quarter

Each $1 of sales, 2025
47%28%25%
Cancer and other testsHereditary testsData for drugmakers

Insurers pay for the tests; drugmakers pay to use the data they produce.

The company · 3 · How does it make money?

Paid per test and per data deal

$1.51Bsales in the past year
About 55%of tests it was paid for, 2023 and 2024
20.4%of data sales from Pathos, the founder's firm, in Q3

Insurers often refuse to pay for a test, so many are run for nothing.

Is it a good business? · 4 · What gives it an edge?

Tests feed data that pays for more tests

About 367,500

cancer samples read in 2025

More than 5,000

hospitals and clinics linked in

87%

of regular doctors still order a year later

Data customers spent 26% more in 2025, on the company's own measures.

Is it a good business? · 5 · What is the catch?

Roche owns the two biggest rivals

Rocheowns Foundation Medicine and Flatiron
Carissells the same tissue report
AstraZenecagot an AI model Tempus built

Listed rivals: ROP.SW · CAI · AZN · NTRA

Tempus's own AI model, delivered to a customer, may become a competitor.

Is it a good business? · 6 · What does its record show?

Revenue quadrupled; losses narrowed

Sales, $B
0.3
0.5
0.7
1.3
1.5
Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Sales$321M → $1.51Bsales, 2022 to the past year
Losses−83% → −18%operating profit per $1
Growth+83%sales growth in 2025, much bought

In the last year selling costs rose per dollar, pay in shares doubled and the operating loss widened.

Is it a good business? · 7 · How much room is there to grow?

Testing is still rare

About 2.11 millionAmericans diagnosed with cancer in 2026
About $3.4Ba year at one test each
91.4%of Medicare cancer patients never tested

Tempus was paid on only about 55% of the tests it ran in 2023 and 2024.

Is it a good business? · 8 · Who is in charge?

The founder controls the vote

2015Eric Lefkofsky founded Tempus
57.9%of the vote he holds, with 21.4% of the shares
Pathoshis other firm, a big data customer

He also chairs Pathos, which supplies about a fifth of data sales.

The story right now · 9 · Why do drugmakers buy data?

Drugmakers pay for real patients' data

26%more spent by data customers in 2025
$42M → $14MRecursion's yearly data fee
21%share jump on another firm's result

Drugmakers use genetic data from real patients to pick which drugs to develop and whom to test them on. Tempus sells that data, and AI makes it more useful.

The story right now · 10 · How fast does Tempus really grow?

Much growth was bought or related

  1. 83.0% reported growth2025.
  2. 33.5% without the purchaseOne February sentence.
  3. A fifth of data from PathosThe founder's firm.
  4. A big data deal endsUnless AstraZeneca extends.

Data licensing above 30% without Pathos, and AstraZeneca extending, would prove us wrong.

The story right now · 11 · What changed lately?

Sales up 23%, loss narrowed

$411.5Msales, up 23.1%
$56.9Moperating loss, narrower
$22.1Mof data sales from Pathos
24.7% to 26.1%fourth-quarter growth the forecast needs

Mixed quarter

The full-year forecast rose again. Personalis holders vote on 30 November.

The story right now · 12 · What is everyone arguing about?

An AI platform growing 25%, or bought growth?

Many investors think

The AI precision-medicine platform growing 25%

We think

Growth bought, partly related-party, slowing elsewhere

One February sentence separates 83.0% reported growth from 33.5% without the purchase.

The price and our view · 13 · What is a share worth?

The price sits far above our best case

$3.22what we think a share is worth
$3.22our value
Attractive
below $2.58
Neutral
Unattractive
above $3.86
$1.53gloomy: growth halves, less kept per $1
$3.22our estimate: experts' path, then slowing
$4.74sunny: growth beats the forecast by a quarter

Value per share in three futures. None is a prediction of the share price.

We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.

The price and our view · 14 · What if it all works?

As a bet on the data platform, it is fragile

Priced for successthe kind of bet this is
1.2×if it works
54%kept if it fails

Multiples of the company's value when the bet was last struck, 30 Sep 2026.

It is worth a little more if the plan works and about half if it fails.

The price and our view · 15 · How could we be wrong?

A renewal that decides the case

AstraZeneca renewalBiggest

Ends at the buyer's choice.

Revenue from the founder's firmShowing now

Pathos.

Getting paidWatch

About half of tests.

Shares for PersonalisUnknown

Depends on the price.

Its own AI model, delivered to a drugmaker, could become a competitor.

The price and our view · 16 · How will we know?

February tests growth without Pathos

Data sales above 30% without PathosGood sign
AstraZeneca extendsGood sign
Another data customer cuts its feeBad sign
FEB 2027-

Fourth-quarter and full-year 2026 results, February. Companies report every three months; each report is a test of the story.

Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.

The price and our view · 17 · So, what do we think?

A large cancer lab, priced as the platform it hopes to be

$3.22our value
Attractive
below $2.58
Neutral
Unattractive
above $3.86

UnattractiveHigh conviction

Tempus runs one of America's largest cancer-testing labs, and every test feeds a data library drugmakers pay for. But much growth was bought, a big data deal ends soon and a fifth of data sales come from a related company.

↑ ↓ to move · C for contents